Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8959754 | Biomaterials | 2018 | 24 Pages |
Abstract
Basic fibroblast growth factor (bFGF) can protect the lung against radiation-induced pulmonary vascular endothelial apoptosis and subsequent radiation-induced lung injury (RILI). However, guiding bFGF to pulmonary vascular endothelial cells is a key determinant for the success of bFGF therapy. To improve the lung-targeting ability of bFGF, a lung endothelial cell-targeting peptide was fused to bFGF (LET-bFGF). An in vitro biological activity assay indicated that fusion of LET did not affect the bioactivity of bFGF. In addition, the fused protein showed superior lung-targeting ability following intravenous injection. Upon injecting LET-bFGF intravenously after thorax radiation, LET-bFGF could better protect against pulmonary vascular endothelial cell apoptosis as early as 4â¯h post-radiation. Compared with native bFGF, enhanced therapeutic effects of LET-bFGF were also observed in terms of decreased vascular abnormalities, disorganized lung structure, inflammatory cell migration, and lung density at 2 months post-radiation. Therefore, lung endothelial cell-targeted bFGF may represent a promising remedy for RILI.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Dongwei Guan, Junwei Mi, Xi Chen, Yonghui Wu, Yuanjiang Yao, Linjie Wang, Zhifeng Xiao, Yannan Zhao, Bing Chen, Jianwu Dai,